===ADT (ADT ) reported earnings on Thur 27 Feb 25 (b/o)

 

 ADT reports EPS in-line, beats on revs; guides FY25 EPS in-line, revs in-line; announces new $500 mln share repurchase plan

• Reports Q4 (Dec) earnings of $0.20 per share, excluding non-recurring items, in-line with the two analyst estimate of $0.20; revenues rose 7.5% year/year to $1.26 bln vs the $1.23 bln single analyst estimate.
• Co issues in-line guidance for FY25, sees EPS of $0.77-0.85, excluding non-recurring items, vs. $0.81 two analyst estimate; sees FY25 revs of $5.025-5.225 bln vs. $5.04 bln two analyst estimate.
• On Feb. 27, 2025, the Company's Board of Directors announced a share repurchase plan. pursuant to which the Company is authorized to repurchase, through April 30, 2026, up to a maximum aggregate amount of $500 million of shares of Common Stock.

==Block (XYZ) reported earnings on Thur 20 Feb 25 (a/h)

Fintech company Block (SQ) has been trading under a new ticker on the New York Stock Exchange starting Jan. 21: XYZ. 

The company, led by Twitter co-founder Jack Dorsey, has had a history of rebranding itself. In December 2021, the company rebranded and changed its name from Square to Block. 

• Sector: Technology
• Industry: Software - Infrastructure
• HQ: Oakland, California
• https://www.block.xyz

 

EARNINGS MISS: XYZ announced quarterly EPS of $0.71, missing expectations by 18.79%.

The financial services company fell short of net revenue ($6.03 billion vs. the $6.28 billion expected) and adjusted earnings ($0.71 vs. the $0.89 expected). The company, led by chairman and CEO Jack Dorsey, managed to beat on adjusted EBITDA, reporting $757 million (vs. the $741.6 million expected).

GeneDx (WGS) reported earnings on Tue 18 Feb 25 (b/o)

** charts after earnings ** 

Strong Beat, Guidance: This provider of exome and genome tests is a play on the shift toward personalized medicine and earlier intervention.

During the fourth quarter, GeneDx earned an adjusted 77 cents per share, obliterating forecasts for 16 cents, according to FactSet. Earnings flipped from a year-earlier loss of 49 cents. Sales grew almost 65% to $95.6 million, well ahead of calls for $82.2 million.

GeneDx also guided to $350 million to $360 million in full-year sales. The low end of the outlook easily beat analysts' forecast for $340.4 million.

GeneDx uses AI to provide genomics-related diagnostic testing.

GeneDx provides whole genome and exome sequencing to help identify rare diseases, primarily in children. The genome includes all the DNA in the body, while reading the exome involves looking at only the protein-coding genes.

When performed early, genetic testing can lead to answers that help avoid what Chief Executive Katherine Stueland calls a "diagnostic odyssey." The company only tests for diseases where there is a solution — a clinical study, a dietary change or a treatment.

===Nucor (NUE) reported earnings on Mon 27 Jan 25 (a/h)

 

 

Nucor beats by $0.58, beats on revs; market conditions are starting to improve

• Reports Q4 (Dec) earnings of $1.22 per share, $0.58 better than the FactSet Consensus of $0.64; revenues fell 8.2% year/year to $7.08 bln vs the $6.76 bln FactSet Consensus.
• Q1 Outlook: Co expects earnings in the steel mills and steel products segments to be similar in 1Q25 as compared to 4Q24. Earnings in the raw materials segment are expected to decrease in 1Q25 relative to 4Q24. Co expects higher corporate, administrative and tax impacts in Q1 than realized in Q4 which may result in lower net earnings overall.
• "While steel demand softened throughout 2024, market conditions are starting to improve and should gain momentum as we work our way into 2025. The U.S. economy is still on the front end of several steel-intensive megatrends and as America's largest and most diversified steel producer, Nucor is well positioned to supply those needs."

-==NextEra Energy (NEE) reported earnings on Fri 24 Jan 25 (b/o)

• The Co. reports EPS in-line; reaffirms FY25 EPS guidance and long term guidance. Additionally, on conference call says it will collaborate with GE Vernova (GEV); says the two companies plan to collaborate to identify key locations on the energy grid that would benefit from new generation. 

NextEra Energy reports fourth-quarter and full-year 2024 financial results 

• NextEra Energy delivers strong full-year 2024 financial and operational results 

• FPL grows regulatory capital employed by approximately 10% year-over-year and continues to keep customer bills as low as possible while delivering reliable electricity 

• NextEra Energy Resources achieves another record year of new renewables and storage origination, adding more than 12 gigawatts to its backlog 

JUNO BEACH, Fla. - NextEra Energy, Inc. (NYSE: NEE) today reported 2024 fourth-quarter net income attributable to NextEra Energy on a GAAP basis of $1.203 billion, or $0.58 per share, compared to $1.210 billion, or $0.59 per share, for the fourth quarter of 2023. On an adjusted basis, NextEra Energy's 2024 fourth-quarter earnings were $1.095 billion, or $0.53 per share, compared to $1.067 billion, or $0.52 per share, in the fourth quarter of 2023. 

For the full year 2024, NextEra Energy reported net income attributable to NextEra Energy on a GAAP basis of $6.946 billion, or $3.37 per share, compared to $7.310 billion, or $3.60 per share, in 2023. On an adjusted basis, NextEra Energy's full-year 2024 earnings were $7.063 billion, or $3.43 per share, compared to $6.441 billion, or $3.17 per share, in 2023, which represents year-over-year growth in adjusted earnings per share of approximately 8.2%.

NextEra Energy, Inc.
NextEra Energy, Inc. (NYSE: NEE) is a leading clean energy company headquartered in Juno Beach, Florida. NextEra Energy owns Florida Power & Light Company, which is America's largest electric utility that sells more power than any other utility, providing clean, affordable, reliable electricity to more than 6 million customer accounts, or more than 12 million people across Florida. NextEra Energy also owns a competitive clean energy business, NextEra Energy Resources, LLC, which, together with its affiliated entities, is the world's largest generator of renewable energy from the wind and sun and a world leader in battery storage. Through its subsidiaries, NextEra Energy generates clean, emissions-free electricity from seven commercial nuclear power units in Florida, New Hampshire and Wisconsin. A Fortune 200 company, NextEra Energy has been recognized often by third parties for its efforts in sustainability, corporate responsibility, ethics and compliance, and diversity. For more information about NextEra Energy companies, visit these websites: www.NextEraEnergy.com, www.FPL.com, www.NextEraEnergyResources.com.

==Ally Financial (ALLY) reported earnings on Wed 22 Jan 25 (b/o)

 

Ally Financial beats by $0.21, beats on revs; to sell its credit card business to CardWorks

• Reports Q4 (Dec) earnings of $0.78 per share, excluding non-recurring items, $0.21 better than the FactSet Consensus of $0.57; adjusted revenues rose 3.6% year/year to $2.09 bln vs the $2.02 bln FactSet Consensus.
• Also, co and CardWorks announce that they have entered into a definitive agreement for CardWorks, and its wholly-owned bank subsidiary, Merrick Bank, to acquire Ally's credit card business, including a portfolio of $2.3 bln in credit card receivables with 1.3 mln active cardholders as of Dec. 31, 2024.
• "Ally's decision to sell its credit card business is part of our broader strategy to pursue a more focused approach, enabling us to simplify and streamline our structure, prioritize our core businesses, and drive improved returns," said Ally CEO Michael Rhodes. The transaction is expected to close in 2025, subject to the completion of customary closing conditions.
• Co says the sale enables Ally to be more focused on its core businesses; acquisition enhances CardWorks' position as a leading credit card issuer and servicer.

===Amphenol (APH) reported earnings on Wed 22 Jan 25 (b/o)

 

Amphenol beats by $0.05, beats on revs; guides Q1 EPS above consensus, revs above consensus

• Reports Q4 (Dec) earnings of $0.55 per share, excluding non-recurring items, $0.05 better than the FactSet Consensus of $0.50; revenues rose 29.8% year/year to $4.32 bln vs the $4.06 bln FactSet Consensus.
• Co issues upside guidance for Q1, sees EPS of $0.49-0.51, excluding non-recurring items, vs. $0.48 FactSet Consensus; sees Q1 revs of $4.00-4.10 bln vs. $3.93 bln FactSet Consensus.

===Protara Therapeutics (TARA) : Positive results from Phase 2 ADVANCED-2 trial of TARA-002 in patients with NMIBC

• TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures
• 100% six-month landmark complete response rate and 80% complete response rate at any time observed in BCG-Unresponsive patients
• 64% six-month landmark complete response rate and 67% complete response rate at any time observed in BCG-Naïve patients
• 80% reinduction salvage rate and compelling durability observed with 100% of patients maintaining a complete response from three months to six months across BCG exposures
• Favorable safety and tolerability profile with no Grade 2 or greater treatment-related adverse events

 

Company Profile

• Protara Therapeutics
• Industry: Health Care
• Website: https://artaratx.com/

=-=Pure Storage (PSTG) reported earnings on Tue 3 Dec 24 (a/h)

 

 Pure Storage beats by $0.09, beats on revs; guides Q4 revs above consensus 

• Reports Q3 (Oct) earnings of $0.50 per share, excluding non-recurring items, $0.09 better than the FactSet Consensus of $0.41; revenues rose 9.0% year/year to $831.1 mln vs the $814.9 mln FactSet Consensus.
• Subscription annual recurring revenue (ARR) $1.6 billion, up 22% year-over-year.
• Remaining performance obligations (RPO) $2.4 billion, up 16% year-over-year.
• Co issues upside guidance for Q4, sees Q4 revs of $867 mln vs. $855.87 mln FactSet Consensus. Sees Non-GAAP Operating Margin of 15.6%.

=-=Torrid (CURV) reported earnings on Tue 3 Dec 24 (a/h)

 

Torrid misses by $0.04, misses on revs, comps -6.5%; guides Q4 revs below consensus

• Reports Q3 (Oct) loss of $(0.01) per share, $0.04 worse than the FactSet Consensus of $0.03; revenues fell 4.2% year/year to $263.77 mln vs the $284.29 mln FactSet Consensus.
  • Comparable sales decreased -6.5% in Q3.
• Co issues downside guidance for Q4 (Jan), sees Q4 revs of $255-270 mln vs. $289.35 mln FactSet Consensus.

===Okta (OKTA) reported earnings on Tue 3 Dec 24 (a/h)

 

Okta beats by $0.09, beats on revs; guides Q4 EPS above consensus, revs above consensus

• Reports Q3 (Oct) earnings of $0.67 per share, $0.09 better than the FactSet Consensus of $0.58; revenues rose 13.9% year/year to $665 mln vs the $649.74 mln FactSet Consensus.
• RPO, or subscription backlog, was $3.659 billion, an increase of 19% year-over-year. cRPO, which represents subscription backlog expected to be recognized over the next 12 months, was $2.062 billion, up 13% compared to the third quarter of fiscal 2024.
• Co issues upside guidance for Q4, sees EPS of $0.73-$0.74, excluding non-recurring items, vs. $0.67 FactSet Consensus; sees Q4 revs of $667-$669 mln vs. $651.29 mln FactSet Consensus. Sees Current RPO of $2.130 billion to $2.135 billion, representing a growth rate of 9% year-over-year.

=== Gap (GAP) reported earnings on Thur 21 Nov 24 (a/h)

 

Gap beats by $0.14, reports revs in-line, comps +1%; guides FY25 revs above consensus 

• Reports Q3 (Oct) earnings of $0.72 per share, $0.14 better than the FactSet Consensus of $0.58; revenues rose 1.6% year/year to $3.83 bln vs the $3.81 bln FactSet Consensus.
  • TOTAL CONSOLIDATED COMPS: +1%
  • Same Store Comps by segment:
    • Old Navy flat: Sales of $2.2 billion were up 1% compared to last year. Comparable sales were flat. The brand's continued focus on operational rigor and brand reinvigoration drove solid performance in the quarter, despite lapping tougher compares and facing weather-related headwinds.
    • Gap +3%: Third quarter net sales of $899 million were up 1% compared to last year. Comparable sales were up 3% representing the fourth consecutive quarter of positive comparable sales at the brand. Gap's strong product and marketing execution have helped drive continued momentum and consistent results at the brand.
    • Banana Republic -1%: Third quarter net sales of $469 million were up 2% compared to last year. Comparable sales were down 1%. The brand saw strength in its men's business during the quarter and remains focused on fixing the fundamentals.
    • Athleta +5%: Third quarter net sales of $290 million were up 4% compared to last year. Comparable sales were up 5%. As expected, the brand returned to positive comparable sales in the quarter as its new product and marketing are resonating with customers.
• Co issues upside guidance for FY25, sees FY25 revs being up +1.5-2.0% vs prior guidance of "up slightly." We compute new guidance as $15.11-15.19 bln vs. $14.95 bln FactSet Consensus.
• Co raises FY24 gross margin guidance to +220 bps from +200 bps prior guidance.

===Snowflake (SNOW) reported earnings on Wed 20 Nov 24 (a/h)

 

Snowflake beats by $0.05, beats on revs, product revenue up 29% yr/yr; Issues Q4 product revenue guidance of $906-$911 mln and also agrees to acquire Datavolo 

• Reports Q3 (Oct) earnings of $0.20 per share, excluding non-recurring items, $0.05 better than the FactSet Consensus of $0.15; revenues rose 28.3% year/year to $942.1 mln vs the $899.31 mln FactSet Consensus.
• Product revenue of $900.3 million in the third quarter, representing 29% year-over-year growth.
• Net revenue retention rate of 127%.
• 542 customers with trailing 12-month product revenue greater than $1 million.
• Agrees to Acquire Datavolo: Co also announces it has signed a definitive agreement to acquire Datavolo, the company built to rapidly accelerate the creation, management, and observability of multimodal data pipelines for enterprise AI1. With this acquisition, Snowflake will deepen its service in the 'bronze layer' of the data lifecycle and will deliver a simple way for data engineering teams to integrate all of their enterprise systems with Snowflake's unified platform, where they can then unlock data for AI and ML, apps and analytics, and leverage the scale, performance, and built-in governance of the AI Data Cloud. Together, Datavolo and Snowflake will both simplify data engineering workloads and deliver unmatched data interoperability and extensibility - a building block for effective enterprise AI.
• Q4 Outlook: Guides for product revenue of $906-$911 mln and non-GAAP operating margin of 4%.

===Luminar Technologies (LAZR) reported earnings on Mon 11 Nov 24 (a/h)

 

Luminar Technologies misses by $0.01, misses on revs; expects Q4 revs to grow moderately relative to Q3 

• Reports Q3 (Sep) loss of ($0.16) per share, excluding non-recurring items, $0.01 worse than the FactSet Consensus of ($0.15); revenues fell 8.6% year/year to $15.49 mln vs the $17.7 mln FactSet Consensus.
• Co's guidance:
  • Q4 revenue expected to grow moderately relative to Q3.
  • Q4 gross loss expected to improve significantly (down) sequentially.
  • Estimating ~$230-240 mln in cash by year's end (down from $240 mln).

====Applied Optoelectronics (AAOI) reported earnings on Thur 7 Nov 24 (a/h)

 

Applied Optoelectronics misses by $0.04, beats on revs; guides Q4 EPS below consensus, revs in-line 

• Reports Q3 (Sep) loss of $0.21 per share, excluding non-recurring items, $0.04 worse than the FactSet Consensus of ($0.17); revenues rose 4.2% year/year to $65.15 mln vs the $62.6 mln FactSet Consensus.
• Co issues guidance for Q4, sees EPS of ($0.04) to $0.04 vs. $0.06 FactSet Consensus; sees Q4 revs of $94 mln to $104 mln vs. $98.56 mln FactSet Consensus.

===Vital Energy (VTLE) reported earnings on Wed 6 Nov 24 (a/h)

 

Vital Energy Reports Third-Quarter 2024 Financial and Operating Results

• Raises fourth-quarter and full-year 2024 total and oil production forecasts

TULSA, OK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Vital Energy, Inc. (NYSE: VTLE) ("Vital Energy" or the "Company") today reported third-quarter 2024 financial and operating results. Strong performance year-to-date also allowed the Company to increase its fourth-quarter and full-year 2024 production outlook. 

Highlights

• Closed the Point Energy acquisition for total cash consideration of $815 million, exclusive of transaction- related expenses and post-closing adjustments
• Reported net income of $215.3 million, Adjusted Net Income1 of $60.4 million and cash flows from operating activities of $246.2 million
• Generated Consolidated EBITDAX1 of $309.5 million and Adjusted Free Cash Flow1 of $34.0 million
• Reduced lease operating expense ("LOE") to $8.78 per BOE, below guidance of $8.95 per BOE
• Produced Company-record 133.3 thousand barrels of oil equivalent per day ("MBOE/d") and oil production of 59.2 thousand barrels of oil per day ("MBO/d")
• Reported capital investments of $241.9 million, excluding non-budgeted acquisitions and leasehold expenditures
• Increased 2025 oil hedges to approximately 16.1 million barrels at $74.79 per barrel NYMEX WTI
• Reduced methane intensity by 90% from 2019 baseline, as of YE-23

===Wolfspeed (WOLF) reported earnings on Wed 6 Nov 24 (a/h)

 

 Wolfspeed beats by $0.09, misses on revs; guides Q2 EPS in-line, revs below consensus 

• Reports Q1 (Sep) loss of $0.91 per share, excluding non-recurring items, $0.09 better than the FactSet Consensus of ($1.00); revenues fell 1.4% year/year to $194.7 mln vs the $200.39 mln FactSet Consensus.
• Co issues guidance for Q2, sees EPS of ($1.14) - $0.89, excluding non-recurring items, vs. ($0.91) FactSet Consensus; sees Q2 revs of $160 - 200 mln vs. $214.69 mln FactSet Consensus.

==Novo Nordisk (NVO) reported earnings on Wed 6 Nov 24 (b/o)

 

Novo Nordisk reports nine-month results; narrows outlook

• Reports nine-month EPS of DKK16.29 vs DKK13.71 LY; revs of DKK204.7 bln vs DKK166.4 bln LY
  • Sales in North America Operations increased by 31% in Danish kroner (31% at CER). Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years. Sales in International Operations increased by 13% in Danish kroner (15% at CER).
  • Sales within Diabetes and Obesity care increased by 25% in Danish kroner to DKK 191.8 billion (26% at CER), mainly driven by GLP-1 diabetes sales growth of 25% in Danish kroner (26% at CER) and Obesity care growing by 44% in Danish kroner to DKK 43.7 billion (44% at CER). Rare disease sales increased by 3% in both Danish kroner and at CER
• Outlook
  • For the 2024 outlook, sales growth is now expected to be 23-27% at CER, and operating profit growth is now expected to be 21-27% at CER. Growth reported in Danish kroner is now expected to be 1 percentage point lower than at CER growth for sales and 2 percentage points lower for operating profit.

Novo Nordisk (NVO) stock skidded Wednesday on mixed third-quarter results as sales of weight-loss drug Wegovy beat expectations, but Ozempic came in light.

Both drugs use the same active ingredient, semaglutide. Semaglutide mimics a hormone called GLP-1 to improve feelings of satiety and markers of blood sugar. During the September quarter, weight-loss drug Wegovy notched $2.53 billion in sales, according to FactSet. Wegovy sales rocketed more than 84% year over year, and beat forecasts for $2.31 billion.

But Ozempic, the diabetes injection, brought in just $4.36 billion, missing expectations for nearly $4.5 billion. Ozempic sales jumped 28%.

==Super Micro Computer (SMCI) reported earnings on Tue 5 Nov 24 (a/h)

 

Super Micro Computer sees Q1 EPS above consensus; Q1 revs below consensus; sees Q2 EPS and revs below consensus 

• Co issues guidance for Q1 (Sep), sees EPS of $0.75-0.76 vs. $0.73 FactSet Consensus; sees Q1 (Sep) revs of $5.9-6.0 bln vs. $6.44 bln FactSet Consensus.
• Co issues downside guidance for Q2 (Dec), sees EPS of $0.56-0.65 vs. $0.81 FactSet Consensus; sees Q2 (Dec) revs of $5.5-6.1 bln vs. $6.84 bln FactSet Consensus.
• As previously disclosed by the Company, in response to information that was brought to the attention of the Audit Committee of the Company's Board of Directors, the Board of Directors had formed an independent committee (the "Special Committee"). The Special Committee has today provided the following statement to Super Micro, but has not otherwise provided any additional details or information.
• "The Special Committee has completed its investigation based on a set of initial concerns raised by EY. Following a three-month investigation led by Independent Counsel, the Committee's investigation to date has found that the Audit Committee has acted independently and that there is no evidence of fraud or misconduct on the part of management or the Board of Directors. The Committee is recommending a series of remedial measures for the Company to strengthen its internal governance and oversight functions, and the Committee expects to deliver the full report on the completed work this week or next. The Special Committee has other work that is ongoing but expects it to be completed soon."
• Supermicro announced on September 20, 2024, that it received a notification letter from Nasdaq stating that the Company is not in compliance with Nasdaq listing rule 5250(c)(1), which requires timely filing of reports with the U.S. Securities and Exchange Commission (the "SEC"). The September 17, 2024, letter was sent as a result of the Company's delay in filing its Form 10-K. The Company filed a Form 12b-25 on August 30, 2024.
• Under the Nasdaq rules, the Company has 60 days from the date of the notice either to file the Form 10-K or to submit a plan to Nasdaq to regain compliance with Nasdaq's listing rules. If a plan is submitted and accepted, the Company could be granted up to 180 days from the Form 10-K's due date to regain compliance. If Nasdaq does not accept the Company's plan, then the Company will have the opportunity to appeal that decision to a Nasdaq hearings panel.

===BigBear.ai (BBAI) reported earnings on Tue 5 Nov 24 (a/h)

 

BigBear.ai beats by $0.02, misses on revs; reaffirms FY24 revs guidance

• Reports Q3 (Sep) loss of $0.05 per share, $0.02 better than the FactSet Consensus of ($0.07); revenues rose 22.1% year/year to $41.51 mln vs the $45.04 mln FactSet Consensus.
• Co reaffirms guidance for FY24, sees FY24 revs of $165 mln to $180 mln vs. $171.77 mln FactSet Consensus.